がん治療薬の正確な放射線量投与を支援する新しいNIST標準(New NIST Standard Helps Deliver the Right Dosage of Cancer-Fighting Drugs)

ad

2025-06-03 米国国立標準技術研究所(NIST)

がん治療薬の正確な放射線量投与を支援する新しいNIST標準(New NIST Standard Helps Deliver the Right Dosage of Cancer-Fighting Drugs)
Credit: S. Kelley/NIST

米国NISTは、がん治療用放射性同位体アクチニウム225(Ac-225)の正確な投与を可能にする新たな放射能測定標準を開発しました。Ac-225は腫瘍細胞をピンポイントで破壊する「がん治療ミサイル」として注目されますが、放射線の多様性ゆえ測定が難しいとされていました。NISTはTDCR法を用いて正確な崩壊率を測定し、SI基準の標準を確立。これにより放射性医薬品の安全かつ効果的な使用が期待されます。

<関連情報>

225Acとその子孫核種の放射平衡における放射能測定と校正 Activity measurements and calibrations for 225Ac in radioactive equilibrium with its progeny

Denis E. Bergeron, Gulakhshan Hamad, Brittany A. Broder, Jeffrey T. Cessna, Adam J. Pearce, Jerome LaRosa, Leticia Pibida, Rhys Salter, Neha S. Saxena, Brian E. Zimmerman
Applied Radiation and Isotopes  Available online: 9 December 2024
DOI:https://doi.org/10.1016/j.apradiso.2024.111630

Highlights

  • Ac-225 activity was determined by primary liquid scintillation methods.
  • Settings for radionuclide calibrators (“dose calibrators”) were determined.
  • Comparison with Monte Carlo models.
  • An ampoule was submitted to the International Reference System (SIR).

Abstract

The massic activity of 225Ac in 0.1 mol/L HCl was measured by multiple primary methods over four consistent measurement campaigns. Results from the triple-to-double coincidence ratio (TDCR) method of liquid scintillation (LS) counting were in accord with other LS-based primary methods. The calibration of commercial radionuclide calibrators (“dose calibrators”) is described, with discussion of current literature values. Comparisons between experimental ionization chamber and NaI(Tl) well counter responses and benchmarked Monte Carlo models are addressed.

有機化学・薬学
ad
ad
Follow
ad
タイトルとURLをコピーしました